Clinical Trial Search

Primary: Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST]) — 0; 0 participants

Primary: Overall Objective Response — 3; 29; 39 participants

Primary: Age at Baseline — 70 years

Primary: Median Yield of Robot Assisted and Second Look Open Pelvic Lymph Node Dissection to Compare the Lymph Node Yield Achieved — 43; 4 Nodes (Node Yield)

Primary: Number of Participants With Pathologically Proven Lymph Node Metastasis — 1 participants

Primary: Number of Participants With Progression-free Survival at 6 Months — 3 Participants

Primary: Keyword Description of Each Biopsy Sample — 89 percentage significant cancers detected

Primary: Percentage of Participants With Adverse Events (AEs) — 900 Participants

Primary: Response Rate — 11 percentage of participants

Primary: Percentage of Participants With Progression Free Survival (PFS) at 2 Months — 54 % of participants with PFS

Primary: Incidence of Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 3; 9 Participants

Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects

Primary: Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion — 13 Participants

Primary: Median Overall Survival — 13.9 months

Primary: Number of Participants Who Were Progression Free at 2 Months — 23; 22 Participants

Primary: Pathologic Complete Response Rate by Transurethral Resection of Bladder Tumor (TURBT) and Imaging Studies After Chemotherapy — 46 percentage of participants

Primary: Number of Paricipants With Tumour Response Defined as Partial or Complete Response Per the RECIST 1.0 Criteria — 0 participants

Primary: Percentage of Participants With Overall Response — 19.1; NA; NA percentage of participants

Primary: Number of Participants With Adverse Events — 2 Participants

Primary: Number of Participants With Clinically Significant Cancer — 38; 31 Participants

Primary: Percentage of Participants With 2-year Progression Free Survival (PFS) — 71.6; 72.3 percentage of participants

Primary: Number of Participants With Complete Response at 3 Months — 26 Participants

Primary: Objective Response Rate (ORR) — 69.6; 33.3 Percentage of participants

Primary: Number of Participants With Presence of Fluorescence of cT1 RCC in Partial Nephrectomy Specimens — 10 Participants

Primary: Percentage of Participants With Response Defined as the Absence of Residual Muscle Invasive Cancer in Resected Specimen — 38; 53 Percentage of Participants

Primary: Tumor Response Rate — 4.5 percentage of responders

Primary: Absence of Clinically Significant Cancer (CSC) on Control Biopsy at 1-year Follow-up. — 8 Participants

Primary: Occurrence of Urinary Tract Cancer — 0.73; 1.07; 1.34; 1.52 Events per 1000 patient years — p=0.122

Primary: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging…

Primary: Progression Free Survival — 1.9 Months